TY - JOUR A1 - Gohlke, Sabrina A1 - Zagoriy, Vyacheslav A1 - Inostroza, Alvaro Cuadros A1 - Meret, Michael A1 - Mancini, Carola A1 - Japtok, Lukasz A1 - Schumacher, Fabian A1 - Kuhlow, Doreen A1 - Graja, Antonia A1 - Stephanowitz, Heike A1 - Jähnert, Markus A1 - Krause, Eberhard A1 - Wernitz, Andreas A1 - Petzke, Klaus-Juergen A1 - Schürmann, Annette A1 - Kleuser, Burkhard A1 - Schulz, Tim Julius T1 - Identification of functional lipid metabolism biomarkers of brown adipose tissue aging JF - Molecular Metabolism N2 - Objective: Aging is accompanied by loss of brown adipocytes and a decline in their thermogenic potential, which may exacerbate the development of adiposity and other metabolic disorders. Presently, only limited evidence exists describing the molecular alterations leading to impaired brown adipogenesis with aging and the contribution of these processes to changes of systemic energy metabolism. Methods: Samples of young and aged murine brown and white adipose tissue were used to compare age-related changes of brown adipogenic gene expression and thermogenesis-related lipid mobilization. To identify potential markers of brown adipose tissue aging, non-targeted proteomic and metabolomic as well as targeted lipid analyses were conducted on young and aged tissue samples. Subsequently, the effects of several candidate lipid classes on brown adipocyte function were examined. Results: Corroborating previous reports of reduced expression of uncoupling protein-1, we observe impaired signaling required for lipid mobilization in aged brown fat after adrenergic stimulation. Omics analyses additionally confirm the age-related impairment of lipid homeostasis and reveal the accumulation of specific lipid classes, including certain sphingolipids, ceramides, and dolichols in aged brown fat. While ceramides as well as enzymes of dolichol metabolism inhibit brown adipogenesis, inhibition of sphingosine 1-phosphate receptor 2 induces brown adipocyte differentiation. Conclusions: Our functional analyses show that changes in specific lipid species, as observed during aging, may contribute to reduced thermogenic potential. They thus uncover potential biomarkers of aging as well as molecular mechanisms that could contribute to the degradation of brown adipocytes, thereby providing potential treatment strategies of age-related metabolic conditions. KW - Brown adipose tissue KW - Aging KW - Ceramides KW - Sphingolipids KW - Dolichol lipids Y1 - 2019 U6 - https://doi.org/10.1016/j.molmet.2019.03.011 SN - 2212-8778 VL - 24 SP - 1 EP - 17 PB - Elsevier CY - Amsterdam ER - TY - JOUR A1 - Fayyaz, Susann A1 - Japtok, Lukasz A1 - Kleuser, Burkhard T1 - Divergent role of sphingosine 1-Phosphate on insulin resistance JF - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry and pharmacology N2 - Insulin resistance is a complex metabolic disorder in which insulin-sensitive tissues fail to respond to the physiological action of insulin. There is a strong correlation of insulin resistance and the development of type 2 diabetes both reaching epidemic proportions. Dysfunctional lipid metabolism is a hallmark of insulin resistance and a risk factor for several cardiovascular and metabolic disorders. Numerous studies in humans and rodents have shown that insulin resistance is associated with elevations of non-esterified fatty acids (NEFA) in the plasma. Moreover, bioactive lipid intermediates such as diacylglycerol (DAG) and ceramides appear to accumulate in response to NEFA, which may interact with insulin signaling. However, recent work has also indicated that sphingosine 1-phosphate (S1P), a breakdown product of ceramide, modulate insulin signaling in different cell types. In this review, we summarize the current state of knowledge about S1P and insulin signaling in insulin sensitive cells. A specific focus is put on the action of S1P on hepatocytes, pancreatic beta-cells and skeletal muscle cells. In particular, modulation of S1P-signaling can be considered as a potential therapeutic target for the treatment of insulin resistance and type 2 diabetes. KW - Sphingosine 1-phosphate (S1P) KW - Insulin resistance KW - Ceramides KW - Diacylglycerol (DAG) KW - Non-esterified fatty acids (NEFA) KW - Hepatocytes KW - Pancreatic cells KW - Skeletal muscle cells Y1 - 2014 U6 - https://doi.org/10.1159/000362990 SN - 1015-8987 SN - 1421-9778 VL - 34 IS - 1 SP - 134 EP - 147 PB - Karger CY - Basel ER -